Cargando…

Tardive Dyskinesia Following Low-Dose Risperidone

Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rokon, Ahmad E, Alsomali, Faisal A, Alrasheed, Malek A, Alharbi, Abdulrahman D, Alhamadh, Moustafa S, Alqahtani, Abdulmajeed M, Alhamidy, Farah K, Alotaibi, Meshal R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825118/
https://www.ncbi.nlm.nih.gov/pubmed/36628029
http://dx.doi.org/10.7759/cureus.32319
_version_ 1784866568769896448
author Rokon, Ahmad E
Alsomali, Faisal A
Alrasheed, Malek A
Alharbi, Abdulrahman D
Alhamadh, Moustafa S
Alqahtani, Abdulmajeed M
Alhamidy, Farah K
Alotaibi, Meshal R
author_facet Rokon, Ahmad E
Alsomali, Faisal A
Alrasheed, Malek A
Alharbi, Abdulrahman D
Alhamadh, Moustafa S
Alqahtani, Abdulmajeed M
Alhamidy, Farah K
Alotaibi, Meshal R
author_sort Rokon, Ahmad E
collection PubMed
description Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopamine receptor-blocking agents, mainly first-generation antipsychotics or a high-dose, second-generation antipsychotic. We present a case of a 28-year-old female with osteogenesis imperfecta presented later with major depressive disorder with psychotic features. She was given a low-dose second-generation antipsychotic, namely, risperidone (2 mg) for psychosis for a cumulative duration of three months. As a result, she developed extrapyramidal symptoms in the form of akathisia, axial dystonia, involuntary movement of the right hand, and smacking movement of the lips. Symptoms persisted for more than eight weeks despite discontinuing risperidone and switching to quetiapine. After the exclusion of other differential diagnoses, she was labeled as a case of tardive dyskinesia. More studies are needed to assess whether undiscovered contributing factors to tardive dyskinesia exist and to understand how second-generation antipsychotics (SGAs) contribute to the development of tardive dyskinesia.
format Online
Article
Text
id pubmed-9825118
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98251182023-01-09 Tardive Dyskinesia Following Low-Dose Risperidone Rokon, Ahmad E Alsomali, Faisal A Alrasheed, Malek A Alharbi, Abdulrahman D Alhamadh, Moustafa S Alqahtani, Abdulmajeed M Alhamidy, Farah K Alotaibi, Meshal R Cureus Neurology Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopamine receptor-blocking agents, mainly first-generation antipsychotics or a high-dose, second-generation antipsychotic. We present a case of a 28-year-old female with osteogenesis imperfecta presented later with major depressive disorder with psychotic features. She was given a low-dose second-generation antipsychotic, namely, risperidone (2 mg) for psychosis for a cumulative duration of three months. As a result, she developed extrapyramidal symptoms in the form of akathisia, axial dystonia, involuntary movement of the right hand, and smacking movement of the lips. Symptoms persisted for more than eight weeks despite discontinuing risperidone and switching to quetiapine. After the exclusion of other differential diagnoses, she was labeled as a case of tardive dyskinesia. More studies are needed to assess whether undiscovered contributing factors to tardive dyskinesia exist and to understand how second-generation antipsychotics (SGAs) contribute to the development of tardive dyskinesia. Cureus 2022-12-08 /pmc/articles/PMC9825118/ /pubmed/36628029 http://dx.doi.org/10.7759/cureus.32319 Text en Copyright © 2022, Rokon et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Rokon, Ahmad E
Alsomali, Faisal A
Alrasheed, Malek A
Alharbi, Abdulrahman D
Alhamadh, Moustafa S
Alqahtani, Abdulmajeed M
Alhamidy, Farah K
Alotaibi, Meshal R
Tardive Dyskinesia Following Low-Dose Risperidone
title Tardive Dyskinesia Following Low-Dose Risperidone
title_full Tardive Dyskinesia Following Low-Dose Risperidone
title_fullStr Tardive Dyskinesia Following Low-Dose Risperidone
title_full_unstemmed Tardive Dyskinesia Following Low-Dose Risperidone
title_short Tardive Dyskinesia Following Low-Dose Risperidone
title_sort tardive dyskinesia following low-dose risperidone
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825118/
https://www.ncbi.nlm.nih.gov/pubmed/36628029
http://dx.doi.org/10.7759/cureus.32319
work_keys_str_mv AT rokonahmade tardivedyskinesiafollowinglowdoserisperidone
AT alsomalifaisala tardivedyskinesiafollowinglowdoserisperidone
AT alrasheedmaleka tardivedyskinesiafollowinglowdoserisperidone
AT alharbiabdulrahmand tardivedyskinesiafollowinglowdoserisperidone
AT alhamadhmoustafas tardivedyskinesiafollowinglowdoserisperidone
AT alqahtaniabdulmajeedm tardivedyskinesiafollowinglowdoserisperidone
AT alhamidyfarahk tardivedyskinesiafollowinglowdoserisperidone
AT alotaibimeshalr tardivedyskinesiafollowinglowdoserisperidone